The National Department of Health has awarded its latest three-year antiretroviral (ARV) tender, valued at R15.5 billion. This decision leaves several of South Africa’s largest domestic pharmaceutical manufacturers without a contract. The government’s procurement strategy sidelines pharma giants and sparks a fresh debate. This debate pits aggressive cost-saving measures against its stated goal of bolstering local industrial capacity. The tender…